Drug Report History
Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.
The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.
| Version v6-EN | Version v1-EN | |
|---|---|---|
| Language | English | English |
| Date Updated | 2025-03-13 | 2024-12-20 |
| Drug Identification Number | 02248302 | 02229048 |
| Brand name | MULTIHANCE | ISOVUE 370 INJECTION |
| Common or Proper name | Gadobenate Dimeglumine injection | Gadobenate Dimeglumine injection |
| Company Name | BRACCO IMAGING CANADA | BRACCO IMAGING CANADA |
| Ingredients | GADOBENATE DIMEGLUMINE | IOPAMIDOL |
| Strength(s) | 529MG | 76% |
| Dosage form(s) | SOLUTION | LIQUID |
| Route of administration | INTRAVENOUS INTRAVENOUS | INTRAVASCULAR INTRAVASCULAR |
| Packaging sizes (GTIN) | (See additional packaging sizes) | (See additional packaging sizes) |
| Additional packaging sizes | 5ml, 10ml,15ml, 20ml, 50ml | 5ml, 10ml,15ml, 20ml, 50ml |
| ATC code | V08CA | V08AB |
| ATC description | MAGNETIC RESONANCE IMAGING CONTRAST MEDIA | X-RAY CONTRAST MEDIA, IODINATED |
| Reason for shortage | Disruption of the manufacture of the drug. | Disruption of the manufacture of the drug. |
| Anticipated start date | ||
| Actual start date | 2024-12-17 | 2024-12-17 |
| Estimated end date | 2025-02-14 | Unknown |
| Actual end date | ||
| Shortage status | Actual shortage | Actual shortage |
| Tier 3 Status | No | No |
| Company comments | The manufacturing and release of the product at the approved manufacturing site are suspended until issue is identified and resolved. | The manufacturing and release of the product at the approved manufacturing site are suspended until issue is identified and resolved. |
| Health Canada comments |